Jasper Therapeutics, Inc.
JSPR
Rank in Stocks
#26825
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on... Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company’s lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma, as well as conditioning agents for stem cell transplant in patients with sickle cell disease, Fanconi anemia, and severe combined immunodeficiency. Jasper Therapeutics, Inc. was founded in 2018 and is based in Redwood City, California.
Share Price
$16.37
Last synced: 2026-11-09
Market Cap
$18.16M
Change (1 day)
-2.91%
Change (1 year)
862.94%
Country
Stock data: Financial Modeling Prep·Updated ·Not investment advice·How we calculate this
Trade Jasper Therapeutics, Inc. (JSPR)
Category
Healthcare
EPS for Jasper Therapeutics, Inc. (JSPR)
EPS as of June 2026 TTM: $-47.70
According to Jasper Therapeutics, Inc.'s latest financial reports, its current EPS (TTM) is $-47.70. At the end of 2025 the company had an EPS of $-118.50, a decrease compared to its 2024 EPS of $-4.89.
EPS history for Jasper Therapeutics, Inc. from 2019 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-47.70 | -59.75% |
| 2025 | $-118.50 | 2,323.31% |
| 2024 | $-4.89 | -20.87% |
| 2023 | $-6.18 | -40.17% |
| 2022 | $-10.33 | -61.58% |
| 2021 | $-26.89 | -85.31% |
| 2020 | $-183.08 | 0.00% |
| 2019 | 0.00 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -132.83% |
US
|
|
| $-7.07 | -85.18% |
US
|
|
| $-5.29 | -88.91% |
AU
|
|
| $12.88 | -127.00% |
BE
|
|
| $21.56 | -145.20% |
NL
|
Questions about Jasper Therapeutics, Inc.'s earnings per share (EPS)
What is Jasper Therapeutics, Inc.'s earnings per share (EPS)?
Jasper Therapeutics, Inc.'s earnings per share (EPS) over the last twelve months is $-47.70, as of Jun 2026.
What was Jasper Therapeutics, Inc.'s earnings per share (EPS) in 2025?
In 2025, Jasper Therapeutics, Inc.'s earnings per share (EPS) was $-118.50, compared with $-4.89 in 2024.
How has Jasper Therapeutics, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Jasper Therapeutics, Inc.'s earnings per share (EPS) was highest in 2024 ($-4.89) and lowest in 2020 ($-183.08).
How does Jasper Therapeutics, Inc.'s earnings per share (EPS) compare with similar companies?
Jasper Therapeutics, Inc.'s earnings per share (EPS) ($-47.70) is lower than that of all 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.